Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 452 206
Medical Information e-mail: medicalinformationuk@merck.com
Summary of Product Characteristics last updated on the eMC: 06/01/2010
SPC Trusopt 20 mg/ml Eye drops, solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/01/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
Date of revision of text on the SPC:   18-Dec-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 9 (Date of First Authorisation / Renewal of the Authorisation): Renewal Date updated to 11 November 2009, following MA renewal

Updated on 07/07/2009 and displayed until 06/01/2010
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6.1 - List of Excipients
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   24-Jun-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



The changes made to the SmPC are as follows:

Section 1: Product name now in line with QRD guidance.

Section 2: The statement of active substance has been made clearer.

Section 3: Product description has been clarified.

Section 4.2: User Instructions have been extensively revised 

 

 

in order to prevent over-tightening of the cap of the bottle and reinforce the proper sealing technique to the patient.    

 

 

Section 4.4: Clarification that Dorzolamide contains a sulphonamido group. Other minor typographical corrections.

 

 

 

Section 4.6: Includes more detailed information concerning use of product during pregnancy and lactation

Section 4.7: Now states that 

 

no studies on the effects on the ability to drive and use machines have been performed.

 

 

 S

 

 

ection 5.3: Findings in rabbits now included.  

 

 

Section 6.1: Excipients listed in full.

 

 

 

Updated on 19/06/2007 and displayed until 07/07/2009
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 25/05/2007 and displayed until 19/06/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   05/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Information on Paediatric use has been added to sections 4.2, 4.4 and 5.1.
Updated on 04/05/2006 and displayed until 25/05/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   31/07/05
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.2: Usage instructions (step 1 - 9) added (previously described in section 6.6).

-Section 4.3: Revised text in paragraph I.

Section 4.4: Contact lens information (last paragraph) revised/clarified.

Section 4.5: A paragraph of text regarding potential interactions for topical/systemic carbonic anhydrase inhibitors has been removed

Section 4.8: Reformatted to MedDRA, body system and prevelance.

Section 5.1: ATC Code added

Updated on 10/06/2002 and displayed until 04/05/2006
Reasons for adding or updating:
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 8 - MA number
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 04/03/2002 and displayed until 10/06/2002
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 16/08/2001 and displayed until 04/03/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 18/04/2001 and displayed until 16/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 20/02/2001 and displayed until 18/04/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 20/02/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   dorzolamide hydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk